III期结肠癌的辅助化疗:医生们对患者年龄和合并症的重要性是否达成共识?

Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?

作者信息

Keating Nancy L, Landrum Mary Beth, Klabunde Carrie N, Fletcher Robert H, Rogers Selwyn O, Doucette William R, Tisnado Diana, Clauser Steven, Kahn Katherine L

机构信息

Division of General Internal Medicine and the Department of Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, USA.

出版信息

J Clin Oncol. 2008 May 20;26(15):2532-7. doi: 10.1200/JCO.2007.15.9434.

Abstract

PURPOSE

We surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations.

METHODS

National survey of surgeons and medical oncologists caring for patients with colorectal cancer regarding whether they would recommend adjuvant chemotherapy for hypothetical patients with stage III colon cancer who varied by age (55 v 80 years) and comorbid illness (none, moderate, severe congestive heart failure [CHF]). Repeated measures logistic regression was used to assess the influence of patient, physician, and practice characteristics on chemotherapy recommendations.

RESULTS

Of 1,096 physicians, nearly all recommended chemotherapy for patients who were 55 years old with no comorbidity (99.0%), 55-years old with moderate CHF (88.6%), or 80 years old with no comorbidity (92.6%); many fewer recommended chemotherapy for 55-year-old patients with severe CHF (24.9%) or 80-year-old patients with moderate (47.2%) or severe (9.0%) CHF (P < .001). Younger physicians (P < .001) were more likely than others to recommend adjuvant chemotherapy overall, although physician factors explained little of the variability in recommendations.

CONCLUSION

Physicians agree with guidelines recommending adjuvant chemotherapy for young, healthy patients with stage III colon cancer but differ widely on recommendations for patients who are older and sicker. Few physician or practice characteristics were associated with recommendations. For older and sicker patients, the individual physicians seen may have a substantial impact on the likelihood of receiving chemotherapy. Understanding better the sources of variation not explained by patients' clinical characteristics may allow improved tailoring of therapy to patients most likely to benefit.

摘要

目的

我们对癌症医生进行了调查,以了解患者的年龄和合并症如何影响辅助化疗的建议,以及医生或医疗实践特征是否也会影响这些建议。

方法

对治疗结直肠癌患者的外科医生和医学肿瘤学家进行全国性调查,询问他们是否会为年龄(55岁与80岁)和合并症情况(无、中度、重度充血性心力衰竭[CHF])不同的Ⅲ期结肠癌假设患者推荐辅助化疗。采用重复测量逻辑回归来评估患者、医生和医疗实践特征对化疗建议的影响。

结果

在1096名医生中,几乎所有人都为无合并症的55岁患者(99.0%)、有中度CHF的55岁患者(88.6%)或无合并症的80岁患者(92.6%)推荐了化疗;而为有重度CHF的55岁患者(24.9%)或有中度(47.2%)或重度(9.0%)CHF的80岁患者推荐化疗的医生则少得多(P<.001)。总体而言,年轻医生(P<.001)比其他医生更有可能推荐辅助化疗,尽管医生因素对建议的变异性解释很少。

结论

医生们认同为年轻、健康的Ⅲ期结肠癌患者推荐辅助化疗的指南,但对于年龄较大且病情较重患者的建议差异很大。很少有医生或医疗实践特征与建议相关。对于年龄较大且病情较重的患者,所看的个体医生可能对接受化疗的可能性有重大影响。更好地了解患者临床特征无法解释的变异来源,可能有助于更精准地为最可能受益的患者量身定制治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索